# US 2024/0197832 A1 · Methods and materials for treating a stroke

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197832 A1
- Document ID: US20240197832A1
- Status: Published application
- Kind: A1
- Application number: 18/288,452
- Filed: 2022-05-24
- Published: 2024-06-20
- Earliest claimed: 2021-05-24
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education; The United States Government as represented by the Department of Veterans Affairs
- Applicants: University of Pittsburgh – Of The Commonwealth System of Higher Education; The United States Government AS Represented By the Department of Veterans Affairs
- Inventors: Xiaoming Hu; Jun Chen; Lawrence R. Wechsler; Yejie Shi
- Web page: https://patentgrep.com/patent/US20240197832A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 38/2066: {IL-10}
- A61K 9/2853: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1709: {from mammals}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/2026: {IL-4}
- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This document relates to methods and materials involved in treating stroke. For example, nanoparticles (e.g., polymer-coated nanoparticles) designed to deliver two or more poly peptides that are normally secreted from mesenchymal stem cells (MSCs; e.g., MSCs of a human less than 33 years of age)) to the brain are provided as well as methods for using such nanoparticles to treat a mammal (e.g., a human) having or having had a stroke.

## Claims

### Claim 1

A composition comprising two or more populations of nanoparticles, wherein each population of nanoparticles independently comprises a polypeptide selected from the group consisting of a IL-4 polypeptide, a IL-10 polypeptide, a TGFß polypeptide, a IGF1 polypeptide, a draxin polypeptide, a NPTX2 polypeptide, a PTN polypeptide, a TGFB3 polypeptide, a PRXL2A polypeptide, a MMP13 polypeptide, a MMP9 polypeptide, and a ADAM22 polypeptide.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the nanoparticles of said two or more populations of nanoparticles are polymer-coated nanoparticles.

### Claim 3 (depends on 2)

The composition of claim 2, wherein said polymer-coated nanoparticles are polyethylene glycol (PEG)-coated nanoparticles.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said composition comprises a first population of nanoparticles comprising said IL-10 polypeptide, a second population of nanoparticles comprising said TGFß polypeptide, a third population of nanoparticles comprising said IGF1 polypeptide, and a fourth population of nanoparticles comprising said draxin polypeptide.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said composition comprises a first population of nanoparticles comprising said IL-4 polypeptide, a second population of nanoparticles comprising said IL-10 polypeptide, a third population of nanoparticles comprising said TGFß polypeptide, a fourth population of nanoparticles comprising said IGF1 polypeptide, and a fifth population of nanoparticles comprising said draxin polypeptide.

### Claim 6

A composition comprising a plurality of nanoparticles, wherein each nanoparticle comprises at least two polypeptides selected from the group consisting of a IL-4 polypeptide, a IL-10 polypeptide, a TGFß polypeptide, a IGF1 polypeptide, a draxin polypeptide, a NPTX2 polypeptide, a PTN polypeptide, a TGFB3 polypeptide, a PRXL2A polypeptide, a MMP13 polypeptide, a MMP9 polypeptide, and a ADAM22 polypeptide.

### Claim 7 (depends on 6)

The composition of claim 6, wherein each nanoparticle comprises said IL-10 polypeptide, said TGFß polypeptide, said IGF1 polypeptide, and said draxin polypeptide.

### Claim 8 (depends on 6)

The composition of claim 6, wherein each nanoparticle comprises said IL-4 polypeptide, said IL-10 polypeptide, said TGFß polypeptide, said IGF1 polypeptide, and said draxin polypeptide.

### Claim 9 (depends on 1)

A method for treating a mammal having a stroke, wherein said method comprises administering the composition of claim 1.

### Claim 10 (depends on 9)

The method of claim 9, wherein said administering is performed while said mammal is experiencing said stroke.

### Claim 11 (depends on 1)

A method for treating a mammal having had a stroke, wherein said method comprises administering the composition of claim 1.

### Claim 12 (depends on 11)

The method of claim 11, wherein said administering is performed within from about 1 minute to about 72 hours of the mammal experiencing the stroke.

### Claim 13 (depends on 9)

The method of claim 9, wherein said mammal is a human.

### Claim 14 (depends on 9)

The method of claim 9, wherein said stroke is selected from the group consisting of an ischemic stroke, a hemorrhagic stroke, and a ministroke.

### Claim 15 (depends on 9)

The method of claim 9, wherein said method is effective to reduce or eliminate a symptom of stroke in said mammal.

### Claim 16 (depends on 15)

The method of claim 15, wherein said symptom is selected from the group consisting of slurring words, confusion, paralysis of the face, arm, or leg, numbness of the face, arm, or leg, weakness of the face, arm, or leg, problems seeing, headache, stumbling, losing balance when walking, dizziness, and loss of coordination.

### Claim 17 (depends on 9)

The method of claim 9, wherein said method is effective to improve sensorimotor function in said mammal.

### Claim 18 (depends on 9)

The method of claim 9, wherein said method is effective to improve cognitive function in said mammal.

### Claim 19 (depends on 9)

The method of claim 9, wherein said method is effective to improve psychiatric function in said mammal.
